Related Experiment Video
Updated: Aug 13, 2026
14:55
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
Published on: May 12, 2013
Towards genomic drug therapy with antisense oligonucleotides
1Department of Chemistry Turku University, Finland.
Annals of Medicine
|December 1, 1996
Summary
Antisense oligonucleotides offer targeted gene silencing for treating diseases. Challenges in stability, delivery, and understanding mechanisms hinder their therapeutic use, requiring multidisciplinary collaboration.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Antisense oligonucleotides (ASOs) are short nucleic acid sequences designed for sequence-specific gene targeting.
- They function by binding to complementary mRNA or DNA, inhibiting protein synthesis.
- ASOs hold promise for treating viral diseases, cancers, and hereditary conditions.
Purpose of the Study:
- To provide a comprehensive overview of the antisense strategy.
- To bridge the communication gap between chemists, biologists, and physicians in this multidisciplinary field.
- To elucidate the potential and challenges of ASOs as therapeutic agents.
Main Methods:
- Review of current literature on antisense oligonucleotide technology.
- Explanation of the sequence-specific base-pairing mechanism.
- Discussion of challenges including chemical modifications, delivery systems, and mechanism of action.
Main Results:
- ASOs can selectively inhibit gene expression by targeting mRNA or DNA.
- Significant potential exists for ASO therapeutics in various human diseases.
- Technical hurdles such as stability, cellular uptake, and precise mechanisms require further research.
Conclusions:
- Antisense technology presents a powerful approach for targeted gene inhibition.
- Overcoming current technical challenges is crucial for realizing the therapeutic potential of ASOs.
- Interdisciplinary research is essential for advancing antisense oligonucleotide development and application.
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...